INTRODUCTION {#s1}
============

Numerous studies have reported that cancer-related inflammation is an indispensable component of the tumor microenvironment. Cancer causes local or systemic inflammation, ultimately promoting cancer initiation and progression by escaping from the immune system \[[@R1]--[@R3]\]. Additionally, systemic immunoinflammation has been generally accepted to affect the cancer microenvironment in a way that favors proliferation, invasion, and migration of cancer cells, while reducing the response to anticancer agents.

Several systemic immunoinflammatory parameters have been evaluated as candidates for predicting long-term survival in various malignancies because systemic immunoinflammation is considered as a consequence, rather than the cause of cancer \[[@R4]\]. Recently, Hu *et al*. demonstrated that the systemic immune-inflammation index (SII) has a strong independent prognostic value in patients with hepatocellular carcinoma treated with surgery \[[@R5]\]. SII comprises 3 peripheral blood parameters, i. e., platelet, neutrophil, and lymphocyte count, which comprehensively reflect the balance of host immune and inflammatory status. In addition, SII is shown to be more objective and reliable for predicting survival in cancer patients than other hematological parameters, including neutrophil/lymphocyte ratio (NLR) and platelet/lymphocyte ratio (PLR), in which both NLR and PLR are based on two inflammatory cells \[[@R6]--[@R8]\].

Currently, prognostic prediction in cancer patients mainly depends on the Tumor, Node, Metastasis (TNM) staging system, but the final TNM stage is defined by the histological evaluation of resected specimens after surgery \[[@R9]\]. Preoperative prognostic prediction remains difficult, and the definitive predictor of survival in cancer patients is a subject of ongoing debate. SII is an easily obtained, inexpensive, and non-invasive biomarker that could complement TNM stage in the preoperative prediction of survival in cancer patients. In this study, we clarified the prognostic impact of immunoinflammation-based indices, including SII as well as NLR and PLR, in gastric cancer patients who underwent curative laparoscopic gastrectomy.

RESULTS {#s2}
=======

SII and clinicopathological features in overall patients {#s2_1}
--------------------------------------------------------

The relationships between the SII values and clinicopathological characteristics in the 412 patients enrolled in this study are summarized in [Table 1](#T1){ref-type="table"}. Based on the SII cutoff value, 307 patients (74.5%) and 105 patients (25.5%) were classified as having a low SII and a high SII, respectively. SII was significantly associated with age (*p* = 0.024), American Society of Anesthesiologists physical status (ASA-PS) classification (*p* \< 0.001), BMI (*p* = 0.044), white blood cell count (WBC) (*p* \< 0.001), lymphocyte count (*p* \< 0.001), neutrophil count (*p* \< 0.001), platelet count (*p* \< 0.001), tumor size (*p* = 0.002), depth of tumor (*p* \< 0.001), lymph node metastasis (*p* = 0.044), pTNM stage (*p* \< 0.001), C-reactive protein (CRP) level (*p* \< 0.001), NLR (*p* \< 0.001), and PLR (*p* \< 0.001) ([Table 1](#T1){ref-type="table"}).

###### Relationships between SII and clinicopathological features in overall gastric cancer patients

  Characteristics               SII                                                  
  ----------------------------- ----- ---------------------- ----------------------- ---------
  Age (years)                         70 (36--91)            74 (43--90)             0.024
  Gender                                                                             0.648
  Male                          287   212                    75                      
  Female                        125   95                     30                      
  ASA                                                                                \<0.001
  1                             24    20                     4                       
  2                             349   269                    80                      
  3                             39    18                     21                      
  BMI                                 22.5 (14.7--40.4)      21.8 (14.0--32.5)       0.044
  WBC                                 5530 (1830--9280)      6490 (3510--13700)      \<0.001
  Lymphocyte                          1760 (470--3780)       1220 (230--2500)        \<0.001
  Neutroohil                          3169 (1100--6190)      4510 (2650--8494)       \<0.001
  Platelet                            205 (58--460)          251 (119--726)          \<0.001
  Tumor size (mm)                     40 (3--180)            50 (5--170)             0.002
  Differentiation                                                                    0.305
  Well                          81    65                     16                      
  Moderate                      152   108                    44                      
  Poor                          179   134                    45                      
  Depth of tumor                                                                     \<0.001
  T1a-1b                        218   180                    38                      
  2                             54    42                     12                      
  3                             59    37                     22                      
  4a-4b                         81    48                     33                      
  Lymph node metastasis                                                              0.044
  N0                            274   215                    59                      
  N1                            50    36                     14                      
  N2                            45    27                     18                      
  N3                            43    29                     14                      
  Pathological stage                                                                 \<0.001
  1a-1b                         247   203                    44                      
  2a-2b                         73    49                     24                      
  3a-3c                         92    55                     37                      
  CEA antigen (ng/ml)                 3.2 (0.7--106)         3.5 (0.8--163.3)        0.144
  CRP (mg/l)                          0.07 (0.01--6.31)      0.15 (0.01--11.10)      \<0.001
  NLR                                 1.826 (0.648--6.893)   4.660 (1.880--16.043)   \<0.001
  PLR                                 116.9 (43.8--276.9)    212.0 (99.4--992.7)     \<0.001
  Postoperative complications                                                        0.087
  absent                        290   223                    67                      
  present                       122   84                     38                      
  Adjuvant chemotherapy                                                              0.133
  Yes                           114   79                     35                      
  No                            298   228                    70                      

Cox regression analysis of OS in overall patients {#s2_2}
-------------------------------------------------

Univariate analyses revealed that worse OS was significantly associated with older age (*p* = 0.006), high BMI (*p* = 0.046), poor ASA-PS (*p* \< 0.001), large tumor size (*p* \< 0.001), poor differentiation (*p* = 0.004), advanced pTNM stage (*p* \< 0.001), high carcinoembryonic antigen (CEA) level (*p* \< 0.001), high CRP level (*p* \< 0.001), high SII (*p* \< 0.001), high NLR (*p* \< 0.001), high PLR (*p* \< 0.001), postoperative complications (present) (*p* = 0.002), and postoperative adjuvant chemotherapy (yes) (*p* = 0.005). Multivariate analysis revealed that ASA-PS (HR: 3.366, 95.0% CI: 1.917 - 5.911; *p* \< 0.001), tumor differentiation (HR: 1.705, 95.0% CI: 1.087--2.674; *p* = 0.020), pTNM stage (HR: 2.160, 95.0% CI: 1.218--3.758; *p* = 0.008), and CEA (HR: 1.964, 95.0% CI: 1.251--3.083; *p* = 0.003) were the independent prognostic factors for OS ([Table 2](#T2){ref-type="table"}).

###### Univariate and multivariate analyses for OS in overall gastric cancer patients

  Variables                     Patients (*n* = 412)   Category or characteristics   Univariate                  Multivariate                             
  ----------------------------- ---------------------- ----------------------------- ------------ -------------- -------------- -- ------- -------------- ---------
  Age                           112/300                (\<65/≥65)                    2.242        1.268--3.962   0.006             1.576   0.870--2.854   0.134
  Gender                        125/287                (female/male)                 1.389        0.865--2.228   0.174                                    
  BMI                           372/40                 (\>18.5/\<18.5)               1.785        1.009--3.156   0.046             1.696   0.928--3.100   0.086
  ASA                           373/39                 (\<3/≥3)                      4.378        2.613--7.336   \<0.001           3.366   1.917--5.911   \<0.001
  Tumor size                    244/168                (\<5/≥5)                      2.275        1.496--3.460   \<0.001           1.396   0.836--2.332   0.202
  Differentiation               232/180                well & mod/poor               1.85         1.220--2.807   0.004             1.705   1.087--2.674   0.02
  pStage                        320/92                 (1,2/3)                       3.647        2.415--5.509   \<0.001           2.16    1.218--3.758   0.008
  CEA                           318/94                 (\<5.0/?≥5.0)                 2.245        1.467--3.436   \<0.001           1.964   1.251--3.083   0.003
  CRP                           350/62                 (\<0.5/\>0.5)                 2.452        1.555--3.865   \<0.001           1.284   0.750--2.199   0.361
  SII                           307/105                (\<661.9/≥661.9)              2.669        1.755--4.060   \<0.001           1.055   0.510--2.182   0.885
  NLR                           268/144                (\<2.529/≥2.529)              2.465        1.630--3.728   \<0.001           1.571   0.804--3.069   0.187
  PLR                           349/63                 (\<212.1/≥212.1)              2.671        1.680--4.244   \<0.001           1.417   0.780--2.573   0.252
  Postoperative complications   290/122                (absent/present)              1.982        1.300--3.020   0.002             1.474   0.934--2.325   0.095
  Adjuvant                      298/114                (No/Yes)                      1.814        1.193--2.757   0.005             0.979   0.587--1.634   0.936

SII and clinicopathological features in inflammation-stratified patients {#s2_3}
------------------------------------------------------------------------

Based on a CRP level of 0.5 mg/dl, 350 patients (85.0%) were categorized into the non-inflammation group (CRP\<0.5) and 62 patients (15.0%) into the inflammation group (CRP³0.5). In patients without inflammation, 274 patients (78.3%) were classified into the low SII group and the remaining 76 patients (21.7%) were classified into the high SII group; the SII was significantly associated with ASA-PS (*p* = 0.044), WBC (*p* \< 0.001), lymphocyte count (*p* \< 0.001), neutrophil count (*p* \< 0.001), platelet count (*p* \< 0.001), tumor size (*p* = 0.015), CEA (*p* = 0.041), CRP (*p* = 0.014), NLR (*p* \< 0.001), and PLR (*p* \< 0.001).

Among the 62 patients with inflammation, 33 patients (53.2%) were classified into the low SII group and the remaining 29 patients (46.8%) were classified into the high SII group. SII was significantly associated with lymphocyte count (*p* = 0.002), neutrophil count (*p* \< 0.001), platelet count (*p* \< 0.001), depth of tumor (*p* = 0.002), lymph node metastasis (*p* = 0.047), pTNM stage (*p* = 0.001), CRP level (*p* \< 0.001), NLR (*p* \< 0.001), PLR (*p* \< 0.001), and postoperative complications (*p* = 0.024) ([Table 3](#T3){ref-type="table"}).

###### Relationships between SII and clinicopathological features in inflammation-stratified gastric cancer patients

  Characteristics               Without inflammation                                                 With inflammation                                                         
  ----------------------------- ---------------------- ---------------------- ---------------------- ------------------- -- ---- ---------------------- ---------------------- ---------
  Age (years)                                          69.5 (36--91)          73.5 (43--89)          0.081                       74 (56--82)            74 (61--90)            0.374
  Gender                                                                                             0.975                                                                     0.546
  Male                          240                    188                    52                                            47   24                     23                     
  Female                        110                    86                     24                                            15   9                      6                      
  ASA                                                                                                0.044                                                                     0.018
  1                             24                     20                     4                                             0    0                      0                      
  2                             302                    240                    62                                            47   29                     18                     
  3                             24                     14                     10                                            15   4                      11                     
  BMI                                                  22.5 (14.7--40.4)      21.9 (15.4--32.5)      0.067                       22.0 (15.6--28.3)      21.5 (14.0--29.8)      0.703
  WBC                                                  5495 (1830--9280)      6480 (4040--10300)     \<0.001                     6130 (3180--8260)      6730 (3510--13700)     0.066
  Lymphocyte                                           1780 (470--3780)       1220 (230--2270)       \<0.001                     1660 (800--3180)       1220 (450--2500)       0.002
  Neutroohil                                           3125 (1100--6190)      4530 (2710--7537)      \<0.001                     3492 (1710--5770)      4440 (2650--8494)      \<0.001
  Platelet                                             207 (58--460)          248 (123--665)         \<0.001                     199 (94--343)          295 (119--726)         \<0.001
  Tumor size (mm)                                      38 (4--180)            50 (5--150)            0.015                       50 (3--126)            65 (12--170)           0.244
  Differentiation                                                                                    0.501                                                                     0.298
  Well                          73                     59                     14                                            8    6                      2                      
  Moderate                      123                    92                     31                                            29   16                     13                     
  Poor                          154                    123                    31                                            25   11                     14                     
  Depth of tumor                                                                                     0.088                                                                     0.002
  T1a-1b                        200                    166                    34                                            18   14                     4                      
  2                             48                     36                     12                                            6    6                      0                      
  3                             46                     33                     13                                            13   4                      9                      
  4a-4b                         56                     39                     17                                            25   9                      16                     
  Lymph node metastasis                                                                              0.662                                                                     0.047
  N0                            245                    196                    49                                            29   19                     10                     
  N1                            49                     29                     11                                            10   7                      3                      
  N2                            30                     23                     7                                             15   4                      11                     
  N3                            35                     26                     9                                             8    3                      5                      
  Pathological stage                                                                                 0.088                                                                     0.001
  1a-1b                         226                    185                    41                                            21   18                     3                      
  2a-2b                         59                     43                     16                                            14   6                      8                      
  3a-3c                         65                     46                     19                                            27   9                      18                     
  CEA antigen (ng/ml)                                  3.1 (0.7--106)         3.6 (0.8--163.3)       0.041                       3.7 (1.0--76.3)        2.8 (1.3--29.5)        0.323
  NLR                                                  1.784 (0.648--6.894)   3.71 (1.968--16.043)   \<0.001                     2.196 (0.881--3.667)   3.656 (1.880--6.909)   \<0.001
  PLR                                                  117.0 (46.7--276.9)    202.1 (99.4--708.7)    \<0.001                     115.2 (43.8--221.3)    234.0 (119.6--992.7)   \<0.001
  Postoperative complications                                                                        0.955                                                                     0.024
  absent                        257                    201                    56                                            33   22                     11                     
  present                       93                     73                     20                                            29   11                     18                     
  Adjuvant chemotherapy                                                                              0.338                                                                     0.513
  Yes                           91                     68                     23                                            23   11                     12                     
  No                            259                    206                    53                                            39   22                     17                     

Cox regression analysis of OS in inflammation-stratified patients {#s2_4}
-----------------------------------------------------------------

In patients without inflammation, univariate analyses identified that a worse OS was significantly associated with older age (*p* = 0.011), poor ASA-PS (*p* = 0.002), large tumor size (*p* \< 0.001), poor differentiation (*p* = 0.001), advanced pTNM stage (*p* \< 0.001), high CEA level (*p* = 0.001), high SII (*p* = 0.002), high NLR (*p* \< 0.001), high PLR (*p* \< 0.001), and postoperative adjuvant chemotherapy (yes) (*p* \< 0.001). Multivariate analysis revealed that age (HR: 2.088, 95.0% CI: 1.033--4.221; *p* = 0.040), ASA-PS (HR: 2.339, 95.0% CI: 1.026--5.332; *p* = 0.043), tumor differentiation (HR: 1.748, 95.0% CI: 1.014--3.013; *p* = 0.044), and pTNM stage (HR: 2.114, 95.0% CI: 1.103--4.050; *p* = 0.024) were the independent prognostic factors for OS ([Table 4](#T4){ref-type="table"}). The SII was not confirmed to be an independent prognostic factor for OS.

###### Univariate and multivariate analyses for OS in inflammation-stratified gastric cancer patients

  Without inflammation                      With inflammation                                                                                                                                           
  ----------------------------- ----------- ------------------- ------- -------------- --------- -- ------- -------------- ------- -- ------- ------- -------------- ------- -- ------- --------------- -------
  Age                           100/250     (\<65/≥65)          2.395   1.221--4.700   0.011        2.088   1.033--4.221   0.04       12/50   1.511   0.519--4.396   0.449                              
  Gender                        (110/240)   (female/male)       1.266   0.735--2.181   0.395                                          15/47   1.487   0.559--3.955   0.427                              
  BMI                           318/32      (\>18.5/\<18.5)     1.63    0.830--3.201   0.156                                          54/8    3.208   1.050--9.803   0.041      5.055   1.442--17.726   0.011
  ASA                           326/24      (\<3/≥3)            3.3     1.554--7.010   0.002        2.339   1.026--5.332   0.043      47/15   3.711   1.689--8.152   0.001      3.403   1.388--8.342    0.007
  Tumor size                    219/131     (\<5/≥5)            2.515   1.533--4.126   \<0.001      1.473   0.813--2.667   0.201      25/37   1.109   0.502--2.452   0.798                              
  Differentiation               195/55      (well & mod/poor)   2.297   1.384--3.821   0.001        1.748   1.014--3.013   0.044      37/25   1.317   0.602--2.880   0.49                               
  pStage                        285/65      (1,2/3)             3.951   2.421--6.447   \<0.001      2.114   1.103--4.050   0.024      35/27   1.989   0.898--4.273   0.091                              
  CEA                           273/77      (\<5.0/≥5.0)        2.291   1.388--3.781   0.001        1.703   0.994--2.917   0.053      47/17   2.12    0.932--4.822   0.073                              
  SII                           274/76      (\<661.9/≥661.9)    2.229   1.330--3.735   0.002        0.783   0.350--1.751   0.551      33/29   2.776   1.227--6.279   0.014      4.208   1.189--14.887   0.026
  NLR                           241/109     (\<2.529/≥2.529)    2.172   1.327--3.557   0.002        1.755   0.848--3.630   0.13       27/35   2.362   1.016--5.490   0.046      0.602   0.159--2.274    0.454
  PLR                           306/44      (\<212.1/≥212.1)    2.921   1.655--5.157   \<0.001      2.068   1.007--4.245   0.058      43/19   1.467   0.649--3.316   0.358                              
  Postoperative complications   257/93      (absent/present)    1.645   0.977--2.771   0.061                                          33/29   2.126   0.970--4.661   0.060                              
  Adjuvant                      259/91      (No/Yes)            2.794   1.714--4.554   \<0.001      1.355   0.749--2.451   0.315      39/23   0.411   0.165--1.025   0.057                              

On univariate analyses for patients with inflammation, OS was found to be significantly associated with high BMI (*p* = 0.041), poor ASA-PS (*p* = 0.001), high SII (*p* = 0.014), and high NLR (*p* = 0.046). Multivariate analysis revealed that BMI (HR: 5.055, 95.0% CI: 1.442-- 17.726; *p* = 0.011), ASA-PS (HR: 3.403, 95.0% CI: 1.388 --8.342; *p* = 0.007), and SII (HR: 4.208, 95.0% CI: 1.189 --14.887; *p* = 0.026) were the independent prognostic factors of OS.

SII and OS across all patients {#s2_5}
------------------------------

Patients with a low SII had a 3-year OS rate of 86.5% and a 5-year OS rate of 78.9%. In patients with a high SII, the 3-and 5-year OS rates were 74.1% and 54.7%, respectively. The log-rank test demonstrated that patients with a high SII had significantly worse OS than those with a low SII (*p* \< 0.001) ([Figure 1](#F1){ref-type="fig"}).

![Postoperative OS based on SII in overall gastric cancer patients.](oncotarget-11-2625-g001){#F1}

SII and OS in inflammation-stratified groups {#s2_6}
--------------------------------------------

In patients without inflammation, the Kaplan-Meier analysis revealed that the 3- and 5-year OS rates in patients with a low SII were 87.5% and 79.9%, respectively, while for patients with a high SII the 3- and 5-year OS rates were 84.3% and 63.0%, respectively. The log-rank test demonstrated that patients with a high SII had significantly worse OS than those with a low SII (*p* = 0.002) ([Figure 2A](#F2){ref-type="fig"}).

![**Postoperative OS based on SII in gastric cancer patients** without inflammation (**A**) and with inflammation (**B**).](oncotarget-11-2625-g002){#F2}

In patients with inflammation, the Kaplan-Meier analysis revealed that the 3- and 5-year OS rates in patients with a low SII were 79.0% and 70.7%, respectively, and those in patients with a high SII the 3- and 5-year OS rates were 50.0% and 35.8%, respectively. The log-rank test demonstrated that patients with a high SII had significantly worse OS than those with a low SII (*p* = 0.011) ([Figure 2B](#F2){ref-type="fig"}).

Predictive ability of SII, NLR, and PLR for OS in inflammation-stratified patients {#s2_7}
----------------------------------------------------------------------------------

In patients without inflammation, AUCs for SII, NLR, and PLR were 0.565, 0.584 and 0.577, respectively ([Figure 3A](#F3){ref-type="fig"}). Additionally, AUCs for SII, NLR and PLR in patients with inflammation were 0.614, 0.603 and 0.565, respectively. SII consistently had a higher AUC value compare to NLR and PLR in gastric cancer patients with inflammation ([Figure 3B](#F3){ref-type="fig"}).

![**Predictive abilities of SII, NLR, and PLR for OS examined using ROC curve analysis in gastric cancer patients** without inflammation (**A**) and with inflammation (**B**).](oncotarget-11-2625-g003){#F3}

DISCUSSION {#s3}
==========

Previous studies have compared the prognostic impact of inflammation-based parameters, including SII and NLR, in lung, pancreas, ovary, or colon cancer \[[@R10]--[@R13]\]. To our knowledge, however, there are no studies on the most suitable parameter for predicting long-term outcomes in gastric cancer. Thus, in this study, we aimed to clarify the clinical and prognostic values of preoperative systemic inflammatory indicators, including SII, NLR, and PLR, in gastric cancer patients who underwent curative laparoscopic gastrectomy.

Neutrophils play crucial roles in the pathogenesis of cancer by enhancing the proliferation, invasion, and metastasis of cancer cells via the release of cytokines and chemokines such as interleukin (IL)-6 and tumor necrosis factor-α (TNF-α). Furthermore, these inflammatory cytokines/chemokines promote angiogenesis and cellular DNA damage, inhibit apoptosis, and protect cancer cells from immune surveillance. As a result, an increasing number of neutrophils can establish a favorable tumor microenvironment and then promote tumor progression \[[@R14], [@R15]\].

Lymphocytes have an important role in tumor immune surveillance and defense against cancer by inducing cytotoxic cell death and inhibiting tumor cell proliferation and migration. Lymphocytes also block the proliferation and migration of cancer cells by secreting cytokines, such as interferon-γ and TNF-α. Thus, lymphocytes can eliminate cancer cells through cellular and humoral immune mechanisms \[[@R16], [@R17]\].

Platelets have been proven to induce epithelial-mesenchymal transition via platelet-derived transforming growth factor-β and direct platelet-tumor cell contact. The complex interaction between tumor cells and platelets favors distant metastasis of tumor cells and allows circulating tumor cells to escape from the host's immune surveillance \[[@R18], [@R19]\].

Based on the facts mentioned above, previous validations had warranted NLR and PLR, which consist of two types of inflammatory cells, to be well associated with cancer cell behavior and prognosis \[[@R10]--[@R13]\]. SII, which comprises 3 peripheral blood parameters, has recently been shown to be a more objective and reliable biomarker for predicting prognosis of cancer patients because it comprehensively reflects both the balance between host inflammatory and immune responses \[[@R5], [@R10]\].

In our study, a high SII was significantly associated with a larger tumor size, deeper invasion, increased lymph node metastasis, and advanced TNM stage in gastric cancer, indicating a more aggressive tumor phenotype. Therefore, SII could be a beneficial complement to TNM stage in the preoperative prediction of survival in cancer patients.

Virchow has reported that inflammatory reactions and cancer, several studies have found that CRP level is a prognostic factor in a variety of cancer \[[@R20]\]. Systemic inflammatory proteins represented by CRP are synthesized by hepatocytes and induced by proinflammatory cytokines, particularly IL-1, IL-6 and TNF-α \[[@R21], [@R22]\]. CRP is directly associated with acceleration of angiogenesis, which enhances the progression and metastasis of malignant tumors and contributes to the progression of cancer. CRP is one of the most frequently used serum markers to evaluate prognosis of cancer, but it lacks specificity and could be elevated in a number of systemic influences such as infections, surgery, and connective tissue disease \[[@R23]--[@R26]\]. CRP is one of the most frequently used serum markers to assess cancer prognosis, but due to lack of specificity, several studies have been reported, including Glasgow Prognostic Score (Glasgow Prognostic Score (GPS) and CRP/albumin ratio (CAR), which combine CRP and albumin \[[@R27]--[@R30]\]. Although the majority of gastric cancer patients have normal CRP, the prognosis prediction by combination of CRP and SII, which comprehensively reflect the balance of host immune and inflammatory status, is important in determining the individualized surveillance and optimized therapeutic strategy to improve prognosis. Inflammatory stratification analysis was performed based on a reference 0.5 mg/dl for CRP, a component of modified GPS reported by Miki et. al \[[@R31], [@R32]\]. In our inflammation-based cohort, NLR, PLR, and SII were associated with OS in univariate Cox analyses, but they inversely failed to achieve statistical significance in patient without inflammation on multivariate analysis and TNM staging remained independent factor at multivariate. On the other hand, only SII remained as an independent factor on multivariate analysis in patients with inflammation, inversely TNM staging was not associated with prognosis in patients with inflammation. CRP alone is unlikely to be a cancer-specific prognostic predictor, but in patients with inflammation, it was possible to predict cancer-specific prognosis when evaluated in combination with SII. In addition, the comparison of AUC using ROC analysis demonstrated that SII was superior to NLR and PLR for predicting OS after surgery in gastric cancer patients with inflammation. In terms of results, the stratification of prognostic prediction based on SII value is rational especially in patients with non-specific inflammation represented by CRP.

Several limitations of this study should be acknowledged. First, this study was conducted with a small sample size in a single institution, which accounts for the lack of statistical power. Second, there are no universal standard cutoff values for inflammation indices. Most studies determined individual cutoff values by their relevance and significance. As a result, there is a wide range of cutoff values for these indices. Significant cutoff values for inflammatory indices should be verified in properly designed multicentric, independent cohort patients before adopting SII as a predictive biomarker in clinical practice. Third, monitoring of SII during perioperative therapy may provide more important information about the status of systemic inflammatory and immune response as well as therapeutic benefit. In this study, we failed to evaluate postoperative dynamic changes in the SII values. Finally, although SII is a useful and readily available routine blood data, the biological and molecular mechanisms that explain the prognostic predictive nature of SII have not been examined. Furthermore, in overall patients, multivariate analysis showed that SII was an independent prognostic factor for cancer-specific survival, but inflammation stratified analysis did not confirm that SII was an independent prognostic factor for cancer-specific survival (CSS), as only patients without inflammation were significantly associated with CSS (data unshown).

In summary, this study showed that preoperative SII is the most significant prognostic biomarker for OS, especially in patients with gastric cancer with inflammation, when compared to two-factor markers such as NLR and PLR. In the future, properly designed prospective studies should confirm the more significant prognostic value of SII in gastric cancer.

MATERIALS AND METHODS {#s4}
=====================

Patients {#s4_1}
--------

This retrospective study evaluated 412 consecutive patients who underwent curative laparoscopic gastrectomy for histologically verified gastric adenocarcinoma at our institution between January 2010 and December 2017. Exclusion criteria were as follows: neoadjuvant chemotherapy; active infection within 1 month before surgery; inflammatory, bone marrow, hematological, or autoimmune disease; and a history of other malignancies within the preceding 5 years.

The extent of the gastrectomy and lymph node dissection were determined in accordance with the Japanese Gastric Cancer Treatment Guidelines (version 4) \[[@R33]\]. Similarly, postoperative adjuvant and post recurrence chemotherapy were administered according to the guidelines \[[@R33]\]. Postoperative complications were evaluated according to the Clavien-Dindo (CD) classification and serious complications were defined as grade II or higher \[[@R34]\]. Clinicopathological classification was assessed according to the International Union Against Cancer Tumor, Node, Metastasis (TNM) classification (seventh edition) \[[@R9]\].

The retrospective protocol of this study was approved by the Ethical Review Board of Shimane University, Faculty of Medicine (Shimane, Japan), and the study is registered with the University Hospital Medical Information Network Clinical Trials Registry (UMIN000030472). The requirement for written informed consent was waived because of the retrospective nature of the study.

Hematological parameter calculation {#s4_2}
-----------------------------------

Preoperative complete blood count (CBC) and blood differential count were derived within 7 days prior to surgery from each patient. The SII was defined as follows: SII = platelet count × neutrophil/lymphocyte count. The NLR and PLR were defined as follows: NLR = neutrophil/lymphocyte count and PLR = platelet/lymphocyte count.

The receiver operating characteristic (ROC) curve was employed in determining the optimal cutoff value for each inflammation-based index for predicting overall survival (OS) after surgery. The optimal cutoff values were 661.9 for SII, 2.529 for NLR, and 212.1 for PLR, respectively. Consequently, patients were divided into a low or high group according to the individual optimal cutoff values for SII, NLR, and PLR. The area under the curves (AUC) for SII, NLR and PLR were 0.599, 0.613 and 0.593, respectively ([Figure 4](#F4){ref-type="fig"}).

![Predictive abilities of SII, NLR, and PLR for OS examined using ROC curve analysis in overall gastric cancer patients.](oncotarget-11-2625-g004){#F4}

Follow-up after surgery {#s4_3}
-----------------------

Patients were carefully followed up after surgery every 3 months for 2 years, and then every 6 months from years 3 to 5. The routine assessment for recurrence included blood examination, abdominal ultrasonography, chest X-ray imaging, and/or computed tomography. The OS was calculated from the date of surgical resection to the date of death from any cause or the date of last follow-up. The median follow-up duration was 35.9 months (range: 2.7--96.6 months).

Statistical analysis {#s4_4}
--------------------

The differences between the categorical variables were evaluated by using the Chi-squared test or Fisher's exact test. The Kaplan-Meier method was used to plot OS after surgery. The differences between survival curves were evaluated via the log-rank test. Cox proportional hazards regression models and Hazard ratios were calculated to test differences between groups. Variables with a *p*-value \< 0.05 following univariate analysis were subsequently subject to multivariate logistic regression analysis. All statistical analyses were performed using JMP software (version 15 for Windows; SAS Institute) and a *p*-value \< 0.05 was considered as statistically significant.
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ASA-PS

:   American Society of Anesthesiologists physical status

AUC

:   area under the curve

BMI

:   body mass index

CAR

:   CRP/albumin ratio (CAR),

CD

:   Clavien--Dindo

CEA

:   carcinoembryonic antigen

CRP

:   C-reactive protein

CSS

:   cancer-specific survival

GPS

:   Glasgow Prognostic Score

HR

:   hazard ratio

IL

:   interleukin

NLR

:   neutrophil/lymphocyte ratio

OS

:   overall survival

PLR

:   platelet/lymphocyte ratio

RBC

:   red blood cell

SII

:   systemic immune-inflammation index

ROC

:   receiver operating characteristic

TNF-α

:   tumor necrosis factor-a

TNM

:   tumor--node--metastasis

WBC

:   white blood cell count
